Clinicopathological significance of Alpha-2-glycoprotein 1 expression in triple-negative breast cancer

Clinicopathological significance of Alpha-2-glycoprotein 1 expression in triple-negative breast cancer - Significance of Alpha-2-glycoprotein 1 expression in breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046081

Enrollment

Registered

2021-12-01

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Triple-negative breast cancer (TNBC) patients who underwent initial histological diagnosis of breast cancer at Tokai University Hospital and who underwent surgery for breast cancer after preoperative chemotherapy (NAC)

Exclusion criteria

Exclusion criteria: 1) Under 20 years old 2) Bilateral breast cancer regardless of whether it is metachronous or simultaneous. 3) Cases with biopsy before NAC performed at institute other than Tokai University hospital. 4) Cases who underwent surgery after NAC outside the Tokai University hospital.

Design outcomes

Primary

Measure	Time frame
Percentage of post-NAC pathological complete response (pCR rate) according to ZAG expression in pre-NAC primary lesions	—

Secondary

Measure	Time frame
Correlation of ZAG expression and Androgen receptor (AR) in pre-NAC primary lesions Correlation between ZAG expression and various immune markers (TIL, PDL-1) in pre-NAC primary lesions Relationship between ZAG expression in the pre-NAC primary lesion and various clinical pathological findings including prognosis Changes in ZAG, AR, Tumor Infiltrating Lymphocytes (TIL), and PDL-1 in breast cancer tissue before and after NAC Differences in the clinical pathological significance of ZAG with and without expression of prolactin inducible protein (PIP)	—

Measure

Time frame

Correlation of ZAG expression and Androgen receptor (AR) in pre-NAC primary lesions Correlation between ZAG expression and various immune markers (TIL, PDL-1) in pre-NAC primary lesions Relationship between ZAG expression in the pre-NAC primary lesion and various clinical pathological findings including prognosis Changes in ZAG, AR, Tumor Infiltrating Lymphocytes (TIL), and PDL-1 in breast cancer tissue before and after NAC Differences in the clinical pathological significance of ZAG with and without expression of prolactin inducible protein (PIP)

—

Countries

Japan

Contacts

Public ContactToru Hanamura

Tokai University School of Medicine Department of Breast Oncology

hanamura.toru.w@tokai.ac.jp0463-93-1121

Outcome results